We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+18.81%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.59B
AUM Growth
+$289M
Cap. Flow
+$97.5M
Cap. Flow %
3.76%
Top 10 Hldgs %
46.26%
Holding
80
New
11
Increased
26
Reduced
24
Closed
16

Top Buys

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$75.7M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$51.8M
3
XNCR icon
Xencor
XNCR
+$48.5M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$48.4M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$39.6M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$89.8M
2
AZN icon
AstraZeneca
AZN
+$70.2M
3
CELG
Celgene Corp
CELG
+$68.1M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$61.8M
5
CTLT
CATALENT, INC.
CTLT
+$34.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.32%
2 Financials 0.74%
3 Communication Services 0.37%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
$38.4M 1.48%
2,955,565
+953,300
+48% +$11.8M
CBIO
27
Crescent Biopharma
CBIO
$602M
$37M 1.43%
22,823
+3,516
+18% +$7.31M
EPZM
28
DELISTED
Epizyme, Inc
EPZM
$35.7M 1.38%
2,011,989
+86,300
+4% +$1.46M
UNH icon
29
UnitedHealth
UNH
$382B
$31.1M 1.2%
145,420
-3,200
-2% -$731K
OXFD
30
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$30.7M 1.19%
2,469,687
+151,300
+7% +$1.84M
JNCE
31
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$26.4M 1.02%
1,182,393
+202,000
+21% +$4.48M
NITE
32
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$25.4M 0.98%
1,768,946
-3,900
-0.2% -$53.2K
ELGX
33
DELISTED
Endologix Inc
ELGX
$25.1M 0.97%
592,316
-494
-0.1% -$21.2K
IFRX icon
34
InflaRx
IFRX
$256M
$24.5M 0.95%
851,100
-6,200
-0.7% -$163K
SYRS
35
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$21.4M 0.83%
165,224
+101,501
+159% +$11.1M
PRAH
36
DELISTED
PRA Health Sciences, Inc.
PRAH
$20.4M 0.79%
245,314
-5,300
-2% -$471K
MDRX
37
DELISTED
Veradigm Inc. Common Stock
MDRX
$20.1M 0.78%
1,626,900
-143,700
-8% -$2.04M
CMRX
38
DELISTED
Chimerix, Inc.
CMRX
$19.4M 0.75%
3,728,690
-104,088
-3% -$527K
ARGX icon
39
argenx
ARGX
$57.4B
$19.2M 0.74%
238,600
+38,600
+19% +$2.92M
EHTH icon
40
eHealth
EHTH
$42.5M
$19M 0.74%
1,330,495
-228,419
-15% -$3.76M
HSKA
41
DELISTED
Heska Corp
HSKA
$18.9M 0.73%
238,446
+42,050
+21% +$3.08M
DCPH
42
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$16.5M 0.64%
821,280
+137,400
+20% +$3.48M
VTRS icon
43
Viatris
VTRS
$20.1B
$15.7M 0.61%
+381,000
New +$16.2M
LUMO
44
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$14.9M 0.58%
228,244
-4,699
-2% -$333K
ODT
45
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$12.6M 0.49%
594,200
-2,700
-0.5% -$63.7K
ARMO
46
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
$11.2M 0.43%
+298,800
New +$12.6M
TDOC icon
47
Teladoc Health
TDOC
$1.58B
$11M 0.43%
273,200
+123,200
+82% +$4.65M
NVTA
48
DELISTED
Invitae Corporation
NVTA
$10M 0.39%
2,139,520
-82,520
-4% -$589K
CTMX icon
49
CytomX Therapeutics
CTMX
$705M
$9.52M 0.37%
334,680
-84,000
-20% -$2.4M
MODN
50
DELISTED
MODEL N, INC.
MODN
$9.46M 0.37%
523,937
-329,777
-39% -$5.5M
1
2
3 4

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q1 2018 Portfolio in Review

As of Q1 2018, Redmile Group held 80 positions worth $2.59B, up 13% from $2.3B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group deployed $97.5M of net new capital in Q1 2018, opening 11 new positions and adding to 26 existing holdings. Its largest new stake was AveXis, Inc. Common Stock: 636,900 shares worth $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $30.3M trimmed.

  • Redmile Group's largest Q1 2018 buy was AveXis, Inc. Common Stock: 636,900 shares worth $78.7M.
  • Redmile Group added most to Atara Biotherapeutics in Q1 2018, an estimated $51.8M increase.
  • Redmile Group's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $30.3M.
  • Redmile Group fully exited Clovis Oncology, Inc. in Q1 2018, selling an estimated $89.8M.
  • Redmile Group's ten largest holdings make up 46% of its $2.59B portfolio in Q1 2018.
  • Redmile Group opened 11 new positions and closed 16 in Q1 2018.
  • Redmile Group's portfolio value rose 13% quarter-over-quarter to $2.59B.

Based on Redmile Group's 13F filing for Q1 2018, filed 15 May 2018.